New longer-term data reinforce safety of Roche’s satralizumab in adults and adolescents with neuromyelitis optica spectrum disorder
22 mai 2020 01h00 HE
|
F. Hoffmann-La Roche Ltd
Pooled data from two pivotal Phase III open-label extension (OLE) studies show satralizumab was well-tolerated as a monotherapy or in combination with baseline immunosuppressive therapy in people with...
FDA approves Roche’s Tecentriq as a first-line monotherapy for certain people with metastatic non-small cell lung cancer
19 mai 2020 01h00 HE
|
F. Hoffmann-La Roche Ltd
Tecentriq’s fourth indication in metastatic non-small cell lung cancer and fifth indication in lung cancer overall in the US Approval based on the Phase III IMpower110 study showing Tecentriq...
Roche launches new blood gas digital solution designed to improve patient care
15 mai 2020 01h00 HE
|
F. Hoffmann-La Roche Ltd
Roche v-TAC is a new digital diagnostics solution that allows clinicians to obtain arterial blood gas values from patients in need of blood gas testing via a simpler, less painful and less invasive...
Roche to present first clinical data on novel anti-TIGIT cancer immunotherapy tiragolumab at ASCO
14 mai 2020 01h00 HE
|
F. Hoffmann-La Roche Ltd
Phase II CITYSCAPE trial shows promising results adding tiragolumab to Tecentriq in people with PD-L1-positive metastatic non-small cell lung cancerFull results will be presented in an oral abstract...
Prägende Persönlichkeit in der Firmengeschichte: Roche Ehrenpräsident Fritz Gerber im Alter von 91 Jahren verstorben
11 mai 2020 08h10 HE
|
F. Hoffmann-La Roche Ltd
Basel, 11. Mai 2020 - Am 10. Mai 2020 ist Dr. h.c. Fritz Gerber im 92. Lebensjahr gestorben. Über mehr als zwei Jahrzehnte hatte er in einer aussergewöhnlich erfolgreichen Doppelfunktion als...
A formative figure in the company's history: Roche Honorary Chairman Fritz Gerber dies at the age of 91
11 mai 2020 08h10 HE
|
F. Hoffmann-La Roche Ltd
Basel, 11 Mai 2020 - On May 10th 2020 Dr. h.c. Fritz Gerber died in his 92nd year. For more than two decades, he had shaped Roche's development into a leading global healthcare company in an...
Wechsel in der erweiterten Konzernleitung von Roche
11 mai 2020 01h00 HE
|
F. Hoffmann-La Roche Ltd
Basel, 11. Mai 2020 - Roche gab heute bekannt, dass Michael Varney (1958), seit 2015 Leiter von Genentech Research and Early Development (gRED), das Unternehmen Ende Juli verlassen und in den...
Changes to the Roche Enlarged Corporate Executive Committee
11 mai 2020 01h00 HE
|
F. Hoffmann-La Roche Ltd
Basel, 11 May 2020 - Roche today announced that Michael Varney (1958) Ph.D., and Head of Genentech Research and Early Development (gRED) since 2015, will retire from the company at the end of July. ...
New data at the ASCO20 Virtual Scientific Program reflects Roche’s commitment to accelerating progress in cancer care
07 mai 2020 01h00 HE
|
F. Hoffmann-La Roche Ltd
First clinical data from tiragolumab, Roche’s novel anti-TIGIT cancer immunotherapy, in combination with Tecentriq® (atezolizumab) in patients with PD-L1-positive metastatic non-small cell lung cancer...
Roche’s COVID-19 antibody test receives FDA Emergency Use Authorization and is available in markets accepting the CE mark
02 mai 2020 22h15 HE
|
F. Hoffmann-La Roche Ltd
The serology test has a specificity greater than 99.8% and sensitivity of 100% (14 Days post-PCR confirmation)The high specificity of the test is crucial to determine reliably if a person has been...